GT Biopharma
Tracked across 7 events · 46 articles · First seen Apr 02, 2026 · Last active Jun 11, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
GT Biopharma announced positive topline results from its European 20-HMedIdeS-19 Post Authorization Efficacy Study (PAES) for Imlifidase, a desensitization treatment for highly sensitized kidney transplant patients. The study met its primary objective with 90% one-year…
Impact: GT Biopharma announced positive topline results from its European Post Authorization Efficacy Study for Imlifidase, fulfilling a key requirement for full marketing authorization and boosting its product's market potential.
May 27, 2026 · 6 articles
Business
GT Biopharma, a clinical-stage biotechnology company, announced its management is scheduled to present at two investor conferences in June 2026. These include the 2026 Jefferies Global Healthcare Conference on June 3 in New York and…
Impact: GT Biopharma is the company presenting at investor conferences, aiming to attract investors and potentially increase its stock value by showcasing its clinical-stage pipeline and vision.
Jun 02, 2026 · 6 articles
Business
GT Biopharma, a clinical-stage biotechnology company, announced two separate grants of equity inducement awards to non-executive employees. On May 28, 2026, the company approved options to purchase 16,950 shares at an exercise price of $21.47.…
Impact: GT Biopharma granted equity inducement awards to new non-executive employees, which is a positive move for employee retention and attracting talent, potentially boosting its stock price.
May 29, 2026 · 8 articles
Business
Impact: GT Biopharma>>> divested the European and MENA rights to Imlifidase for 115 million euros, allowing it to focus on other markets and receive significant payments.
May 19, 2026 · 7 articles
Business
Verrica Pharmaceuticals announced that its President and CEO, Jayson Rieger, will present at the Jefferies Global Healthcare Conference on June 4, 2026. The presentation will cover the company's developments in dermatological diseases, including its FDA-approved…
Impact: Verrica Pharmaceuticals has a worldwide license agreement with GT Biopharma for the development and commercialization of VP-315, which may be discussed at the conference.
May 28, 2026 · 6 articles
Business
Oncolytics Biotech>>> announced significant leadership changes, appointing Steve-O>>> to its Board of Directors and promoting John McAdory>>> to Chief Operating Officer. Steve-O>>> brings extensive experience in public company leadership and strategic transactions, including his role…
Impact: GT Biopharma>>> is mentioned as a past company where Steve-O>>> served as Chairman during its acquisition by Johnson & Johnson>>>.
Jun 02, 2026 · 7 articles
100
GT Biopharma announced positive resultsHansa Biopharma Idefirix...
100
GT Biopharma scheduled to presentCrescent Biopharma to present
90
GT Biopharma plans to submit application European Union — European Medicines AgencyHansa Biopharma Idefirix...
80
GT Biopharma approved grant optionsCrescent Biopharma Grants...
NEWSDESK
Track GT Biopharma live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard